Barr Less Certain About Plan B OTC Switch Decision Timeline
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is "not 100% comfortable" that FDA will meet the extended user fee deadline of May 21. CEO Downey says the high-profile nature of the Plan B switch has resulted in sales gains across Barr’s contraceptive business.